Developer docs
API playgroundTry for free, no card

Search company profiles

PST

Full company profile

uuid003dod9

Namestring
PST
Legal namestring
PST株式会社
Websiteurl
medical-pst.com
Company typeenum
Private
Founded yearint
2012
Descriptiontext

PST Inc. is a Yokohama-based biotechnology company founded in 2012 that develops and commercializes vocal biomarker (音声バイオマーカー) technology for medical and healthcare applications. Its core technology analyzes raw voice source signals — specifically involuntary vocal cord tension changes controlled by the vagus nerve, combined with expiratory pressure and vocal tract modulation — to detect mental, neurological, cardiovascular, and systemic health conditions. This analysis is language-agnostic and unaffected by a speaker's intentional voice modulation because it operates on the acoustic source rather than linguistic content. The proprietary Mi-1 AI model and feature extraction algorithms (ALVI, MDVI) are backed by 10+ years of R&D originating from the University of Tokyo voice pathophysiology laboratory, with multiple peer-reviewed publications across depression, heart failure, cognitive impairment, and COVID-19 severity domains.

PST operates two product lines. The first is VOISLOG, a cloud-based healthcare platform launched in July 2024 that includes smartphone voice analysis apps (vAnalysis individual and shared), a remote-meeting voice analysis tool (vBG App integrating Zoom/Teams/Slack/Google Meet/LINE/Webex), an administrative dashboard (vManagement) with monthly Personal Reports, and an EQ quantification module (vEQ). Disease-specific biomarkers (VOISFIA) and legacy MIMOSYS technology serve the medical domain. The second is regulated medical device development via wholly-owned subsidiary PST Medical Inc., established January 2024, which holds a Class II Medical Device Manufacturing and Sales License (obtained June 2024) and is pursuing SaMD approval for depression severity assessment under Tokyo's AMDAP program.

PST generates revenue through VOISLOG cloud subscriptions (enterprise and SMB tiers), OEM/cloud licensing to platform partners (NTT Data BXO, Kort Valuta TwooCa, Wellville LIFE TALK ENGINE), WebAPI licensing, and future regulated SaMD sales via PST Medical. Go-to-market combines enterprise direct sales, channel partners (Hino Computer Systems for transportation), co-development partnerships with strategic players (Rohto Pharmaceutical, WISDOM, Sekisui Chemical, SOMPO), and government/municipal collaborations (Kanagawa Prefecture, Tokyo AMDAP). Customer segments span enterprise employers, transportation/logistics operators, nursing care facilities, SMBs (via government subsidy program), medical institutions, and local governments. The company received the EY Innovative Startup 2026 award and ASCO Breakthrough 2024 Abstract Award, among other recognitions.

Short descriptiontext

PST Inc. is a Yokohama-based biotechnology company that develops vocal biomarker technology analyzing voice source features to detect mental, neurological, cardiovascular, and cognitive health conditions, serving enterprise employers, transportation operators, medical institutions, and municipalities via its VOISLOG cloud platform and regulated SaMD programs.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersYokohama, Japan
HQ citystring
Yokohama
HQ countrystring
Japan
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
vocal biomarker technology, voice-based health diagnostics, cloud health monitoring platform, medical software devices, enterprise wellness analytics
Industry4 codes
PRIMARYHLACANAF
SaMD – Digital Biomarkers & Algorithmic Endpoints
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAD
Software as a Medical Device (SaMD) – Clinical Decision & Diagnostic Software
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAE
SaMD – Monitoring, Triage & Risk Stratification Software
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLALADAD
Chronic Condition Management & Remote Monitoring (e.g., diabetes, HTN)
Healthcare & Life Sciences/Telehealth Platforms/Employer-Sponsored Virtual Care Platforms
NAICS code1 code
  • Software Publishers5132
SIC code1 code
  • Services-Prepackaged Software7372
Product category
Voice-Based Health Diagnostics and Wellness Software
Social media profiles2 records
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model5 records
1VOISLOG cloud platform subscription
TypeSubscription Recurring
Description

VOISLOG is offered as a cloud-based SaaS platform with multiple apps (vAnalysis shared, vBG App) and management console (vManagement). Customers subscribe to access voice AI analysis and reporting. Revenue is primarily subscription-based with per-seat or organization-level pricing.

medical-pst.com
2IT導入支援事業者 subsidy (VOISLOG Standard Pack)
TypeSubscription Recurring
Description

VOISLOG標準パック[vAs+vM] is registered as an IT tool under the 中小企业デジタル化・AI導入支援事業費補助金, enabling SME customers to receive up to ¥1.5M in government subsidies toward subscription costs.

medical-pst.com
3OEM/cloud system licensing
TypeLicensing Royalties
Description

PST provides cloud systems and WebAPI to OEM partners (enterprises, platforms) who embed voice biomarker technology into their own products and services. Partners integrate via API and pay licensing fees.

medical-pst.com
4Medical device software (SaMD) development and sales (PST Medical)
TypeSubscription Recurring
Description

PST Medical (subsidiary) is developing regulated medical device programs (Software as a Medical Device) for depression severity assessment and other clinical applications. Business model targets medical institutions and healthcare providers upon regulatory approval.

pstmd.medical-pst.com
5Platform integration services (TwooCa, BXO)
TypeLicensing Royalties
Description

PST technology embedded in partner platforms (Kort Valuta TwooCa, NTT Data BXO) as licensed voice analysis engine, generating recurring licensing revenue from platform operators.

medical-pst.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components1 value
Technology or R&D
Pricing details1 tier
1VOISLOG標準パック [vAs+vM] — voice analysis app (vAnalysis shared) + management console (vManagement)
ModelSubscriptionBilling cadenceAnnual
Notes

Eligible for IT導入支援事業者 subsidy of up to ¥1,500,000 under the 中小企业デジタル化・AI導入支援事業費補助金2026. Subscription pricing not publicly disclosed; SME customers can offset cost via government subsidy.

medical-pst.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 5 records shown
1VOISLOG®
Description

日常会話などの音声を解析しストレス、睡眠、認知機能などの健康指標を推定するクラウドベースの音声解析プラットフォーム。スマートフォンアプリ(vAnalysis、vAnalysis shared)、リモート会議ツール(vBG App)、WebAPI管理システム(vManagement)を含む。

medical-pst.com
+4 more records
Core offering1 text field

PST develops and sells a cloud-based vocal biomarker platform called VOISLOG that analyzes voice source features (not linguistic content) to detect mental, cognitive, cardiovascular, and physiological health conditions for enterprise wellness, transportation safety, elderly care, and clinical psychiatry applications. Through its subsidiary PST Medical, the company develops regulated Software as a Medical Device (SaMD) programs for depression severity assessment and cognitive screening, and operates the MIMOSYS legacy voice-based mental health monitoring system. Revenue is generated via SaaS subscriptions, OEM/API licensing, and government-subsidized SME deployments in Japan.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Depression estimation: Pearson r=0.579; ROC-AUC 0.793 (HAM-D≥8), 0.780 (HAM-D≥14). Inter-visit monitoring: correlation 0.62, AUC=0.82, 77% accuracy, marginal R²=0.37 for symptom change prediction.
+4 more records
Product overview1 text field

PST Inc. operates as a vocal biomarker technology company offering two distinct product lines: (1) VOISLOG, a cloud-based healthcare voice analysis platform for corporate health management and wellness, and (2) disease-specific vocal biomarker technologies (VOISFIA) and medical device programs (SaMD) for the medical domain via its subsidiary PST Medical Inc. VOISLOG comprises multiple modules — voice analysis apps (vAnalysis individual and shared for shared devices), meeting-based analysis app (vBG App), administrative dashboards (vManagement), monthly Personal Report, and the vEQ emotional intelligence module — unified by the Mi-1 voice AI model. MIMOSYS is the legacy healthcare product. PST Medical focuses on clinical-grade depression severity assessment and cognitive screening as regulated medical devices. All technologies analyze raw voice source signals (not text) to detect involuntary physiological changes indicative of mental and physical health conditions.

Product and service11 records
1VOISLOG Healthcare Platform
CategoryCloud Voice Analysis Platform
Description

Cloud-based voice analysis platform that visualizes mental and physical health conditions (stress, cognitive function, sleep, swallowing) from voice for corporate health management and wellness. Provides voice biomarker analysis via smartphone apps, remote meeting tools, WebAPI, and management dashboards for enterprise customers.

2Depression Severity Assessment Tool (PST Medical SaMD)
CategoryMedical Device Software (SaMD)
Description

Medical device program under development by PST Medical Inc. for depression severity assessment using voice biomarkers. Estimates HAM-D scores with r=0.579 Pearson correlation and ROC-AUC 0.78-0.80 for HAM-D thresholds. Targeting SaMD approval for use by psychiatric hospitals and clinics.

3Heart Failure Vocal Biomarker (VOISFIA)
CategoryMedical Diagnostic Biomarker Module
Description

Disease-specific vocal biomarker for heart failure developed with Yokohama City University. Uses machine learning models with voice acoustic features to predict BNP levels (r=0.49) and NYHA class, achieving up to 80.4% accuracy in predicting cardiac test results for clinical use.

4vAnalysis shared (Shared-Device Voice Analysis App)
CategoryWorkplace Voice Analysis Application
Description

Voice analysis app optimized for shared device use in workplace settings (transportation, call centers, enterprises). Allows approximately 50 users per shared tablet/phone with guided reading or free speech measurement, auto-login, brief result display, and automatic logout for secure multi-user operation.

5vBG App (Meeting Voice Analysis App)
CategoryRemote Meeting Voice Analysis Software
Description

Desktop voice analysis app that runs in the background during remote or in-person meetings on Zoom, Microsoft Teams, Slack, Google Meet, LINE, and Webex. Automatically captures the registered user's voice only and analyzes stress and mental/physical condition changes without user intervention.

6vManagement Personal Report
CategoryHealth Reporting Service
Description

Monthly structured personal health report feature within vManagement. Consolidates 1 month of voice analysis results, providing numerical/graphical trends plus natural language commentary authored with occupational health expert input, including self-care action recommendations.

7vEQ (Vocal Emotional Intelligence Quotient Service)
CategoryHR Analytics Software
Description

Voice-based Emotional Intelligence Quotient quantification service co-developed with WISDOM. Quantifies empathy from voice using the 'vEQ' empathy analysis algorithm (patent pending). Targets HR, talent development, and organizational EQ building for enterprise customers.

8MIMOSYS (Mind Monitoring System)
CategoryVoice-Based Mental Health Monitoring Software
Description

PST's foundational voice-based mental health assessment technology that visualizes mental states by analyzing voice changes including involuntary vocal cord tension. Exports Vitality, Mental Activity, and Mind Index scores. Available via SDK, WebAPI, and applications for healthcare and enterprise customers.

9VOISLOG × TwooCa Ring Integration
CategoryComposite Wearable-Voice Health Solution
Description

Integrated product combining VOISLOG voice biomarker analysis with the TwooCa Ring wearable device (Kort Valuta), merging voice analysis data with vital signs to generate composite health scores spanning physical, mental, and financial wellness for enterprise employees.

10VOISLOG Standard Pack [vAs+vM]
CategorySubsidized SMB Cloud Health Package
Description

Standardized IT tool package combining vAnalysis shared (vAs) and vManagement (vM) cloud services for SMEs. Registered as an approved IT tool under Japan's SMB Digitalization/AI Adoption Subsidy program, enabling eligible businesses to receive up to 1.5 million yen in government subsidies.

11Cognitive Impairment Screening Vocal Biomarker (VOISFIA)
CategoryMedical Diagnostic Biomarker Module
Description

Disease-specific vocal biomarker for mild cognitive impairment (MCI) and dementia (Alzheimer's, DLB) developed with academic partners. Uses non-verbal acoustic features from simple speech tasks in machine learning models. Achieved mean AUC of 0.81 and 66.7% three-group correct classification (healthy/MCI/dementia) in validation.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership18 partners
1E-Gaia Progress (株式会社イーガイアプログレス)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-06-02
Description

Joint development of municipality/community mental health and well-being support services. Combine PST's VOISLOG platform with E-Gaia Progress's auto-call and WELLXiL mental health services. Target: elderly monitoring, community care, ME-BYO improvement. Extension of existing enterprise mental health partnership.

medical-pst.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-27
Description

Joint development of vEQ (Vocal Emotional Intelligence Quotient) algorithm for quantifying empathy and EQ from voice. Patent filed jointly (特願2025-191230). WISDOM provides EQ training expertise; PST provides voice analysis technology. Target: enterprise EQ training (2026) and HR tech (2027+).

3Hino Computer Systems (日野コンピューターシステム)
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-04-27
Description

Sales agent agreement for VOISLOG platform. Hino CS — IT provider within Hino Motor Group — distributes VOISLOG to transportation companies and other industries for driver condition monitoring at shift check-in and accident prevention.

medical-pst.com
4Tokyo Marine DR (東京海上ディーアール)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-08-29
Description

Collaboration on enterprise health management consulting. Combines Tokyo Marine DR's risk consulting expertise with PST's voice biomarker technology for corporate wellness programs targeting mental health, turnover reduction, and accident prevention in call centers and logistics.

medical-pst.com
5Kanagawa Prefecture (神奈川県)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-05-30
Description

Formal partnership agreement for voice-based ME-BYO indicator regional deployment. Upgrade of MIMOSYS to VOISLOG Mi-1. Collaboration on ME-BYO brand expansion, stress/cognitive/sleep/oral health service rollout, and community health improvement across Kanagawa Prefecture.

medical-pst.com
6Rohto Pharmaceutical Co., Ltd. (ロート製薬)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-02-19
Description

Strategic alliance to integrate vocal biomarker technology into Rohto's health and wellness ecosystem. Combined expertise aimed at developing products and services for mental health and preventive care, leveraging Rohto's pharmaceutical and consumer health platform.

medical-pst.com
7Tokyo Metropolitan Government (AMDAP program)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-10-24
Description

PST Medical selected for Tokyo's Advanced Medical Device Acceleration Project (AMDAP). Receives 3-year intensive support including dedicated catalyst (regulatory expert) mentoring, clinical/regulatory/IP/business guidance for developing depression severity SaMD.

pstmd.medical-pst.com
8Total Future Healthcare (トータルフューチャーヘルスケア)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-10-04
Description

PST participates in Total Future Healthcare's cross-industry platform for early detection of falls and disease risk in living spaces. PST contributes voice biomarker data for health monitoring within the platform ecosystem.

medical-pst.com
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-07-26
Description

Capital and business alliance. PST technology integrated into Kort Valuta's TwooCa digital employee badge (Visa payment + attendance + mental health check). Also Kort Valuta ring vital data + VOISLOG integration planned. FinTech × HealthTech partnership for 'money, body, mind' health.

10Sekisui Chemical (積水化学工業)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-06-03
Description

Joint development of cognitive function screening voice analysis algorithm. Clinical trial for cognitive function testing medical device initiated. Sekisui Chemical and PST co-developing the algorithm for commercialization.

medical-pst.com
11UIX Corporation (UIX株式会社)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-07-01
Description

Joint venture (PST + FlexibleCreation) operating 'Sofuto Visiting Nursing Station' in Yokohama Isogo-ku. Next-generation visiting nursing service combining PST voice analysis, AI/IT technology, and cloud PBX with electric kickboard mobility.

medical-pst.com
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-03-30
Description

MIMOSYS voice biomarker technology OEM-integrated into NTT Data's BXO Hybrid Workspace for Employee Experience (BXO Well-being module). Enables NTT Data to offer voice-based mental health monitoring to enterprise clients in hybrid work environments.

13JST COI-NEXT Metaverse Platform (JST共創の場形成支援プログラム)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-10-25
Description

PST participates in Yokohama City University-led 'Meta Care City' project (JST COI-NEXT 共創分野本格型). Contributes voice pathophysiology analysis as health quantification tool in virtual care environments targeting youth psychological resilience.

medical-pst.com
14SOMPO Holdings / SOMPO Care (積水化学工業+SOMPOケア)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-02-09
Description

Joint R&D on swallowing function evaluation technology using voice analysis via smartphone/tablet. Aimed at visualizing aspiration risk in elderly populations. Planned 2022 commercialization.

medical-pst.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-10-08
Description

Joint research on voice-based QOL management for gynecological cancer patients and depression assessment. Multiple papers published, ASCO Breakthrough Abstract Award received. Co-development of depression severity estimation model with 2026 clinical results published.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Long-standing joint research on heart failure vocal biomarkers with Dr. Kozo Okada. Multiple publications including AHA Scientific Session, Japan Circulation Society, and Circulation Reports. Also collaborated on congenital heart disease seminar (2024).

17Welby (不是我认识的合作伙伴 - listed in joint users)
Strategic tierMinorTypeOthers
Description

Listed in PST privacy policy joint user list.

medical-pst.com
18Kanagawa University of Human Services (神奈川県立保健福祉大学)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Joint research with Prof. Shinichi Tokuno on COVID-19 severity discrimination from voice, published 2023 in Int J Env Res Public Health.

medical-pst.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
1Kintsugi
TypeDirect peer
Description

US-based voice biomarker startup quantifying depression/anxiety from short voice samples for payers and digital health platforms. Closely parallels PST's depression model, enterprise wellness integration and SDK/API distribution.

TypeBroad incumbent
Description

US-based broader digital health platform offering chronic condition prevention and management (diabetes, hypertension, mental health) to employers and payers. Comparable in B2B2C employer-wellness GTM and condition-specific digital interventions, though vaster scale and broader scope.

TypeDirect peer
Description

Canada-based voice biomarker company focused on cognitive and CNS endpoints for clinical trials (Alzheimer's, MCI, schizophrenia). Comparable to PST's cognitive impairment/dementia vocal biomarker module and clinical-research focus.

TypeRegional player
Description

Japanese digital health company offering online medical consultations, remote patient monitoring and AI-assisted triage to hospitals, pharmacies and insurers. Comparable regional peer serving overlapping Japanese enterprise/healthcare buyers with adjacent digital health services.

TypeDirect peer
Description

US-based vocal biomarker startup that analyzes voice to detect depression and anxiety symptoms for health systems and payers. Closely mirrors PST's depression/severe-mental-health scoring use case and clinical validation strategy.

TypeEmerging player
Description

US-based vocal biomarker startup applying voice analysis to early detection of cognitive decline, mental health and neurodegenerative conditions. Overlaps with PST on vocal biomarker R&D focus, though still pre-commercial compared to PST's Japanese deployments.

7CureApp
TypeDirect peer
Description

Japanese digital therapeutics (DTx/SaMD) company with PMDA-approved nicotine-dependence and hypertension apps. Highly comparable to PST Medical on Japanese SaMD regulatory pathway, reimbursement and clinical-deployer GTM.

TypeEmerging player
Description

Israel-based voice analysis company that decodes health and emotional biomarkers from vocal acoustics. Earlier-stage peer in the same vocal biomarker category as PST, with overlapping emotion/mood-disorder detection product thinking.

TypeDirect peer
Description

US-based vocal biomarker company offering voice-based mental and physical health monitoring (depression, stress, cognitive decline, respiratory conditions). Directly comparable to PST on technology approach, biomarker focus areas and SaaS/API delivery model.

TypeOthers
Description

US-based voice analytics company that detects emotion, toxicity and engagement from speech on platforms like Discord and games. Adjacent rather than directly competitive, but comparable as a voice-as-signal AI infrastructure provider powering third-party platforms.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

Integration10 records

Each record includes

Title, Type, Description, Source

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature13 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

PST

Voice-Based Health Diagnostics and Wellness Softwaremedical-pst.com

PST Inc. is a Yokohama-based biotechnology company that develops vocal biomarker technology analyzing voice source features to detect mental, neurological, cardiovascular, and cognitive health conditions, serving enterprise employers, transportation operators, medical institutions, and municipalities via its VOISLOG cloud platform and regulated SaMD programs.

What PST does

PST Inc. is a Yokohama-based biotechnology company founded in 2012 that develops and commercializes vocal biomarker (音声バイオマーカー) technology for medical and healthcare applications. Its core technology analyzes raw voice source signals — specifically involuntary vocal cord tension changes controlled by the vagus nerve, combined with expiratory pressure and vocal tract modulation — to detect mental, neurological, cardiovascular, and systemic health conditions. This analysis is language-agnostic and unaffected by a speaker's intentional voice modulation because it operates on the acoustic source rather than linguistic content. The proprietary Mi-1 AI model and feature extraction algorithms (ALVI, MDVI) are backed by 10+ years of R&D originating from the University of Tokyo voice pathophysiology laboratory, with multiple peer-reviewed publications across depression, heart failure, cognitive impairment, and COVID-19 severity domains.

PST operates two product lines. The first is VOISLOG, a cloud-based healthcare platform launched in July 2024 that includes smartphone voice analysis apps (vAnalysis individual and shared), a remote-meeting voice analysis tool (vBG App integrating Zoom/Teams/Slack/Google Meet/LINE/Webex), an administrative dashboard (vManagement) with monthly Personal Reports, and an EQ quantification module (vEQ). Disease-specific biomarkers (VOISFIA) and legacy MIMOSYS technology serve the medical domain. The second is regulated medical device development via wholly-owned subsidiary PST Medical Inc., established January 2024, which holds a Class II Medical Device Manufacturing and Sales License (obtained June 2024) and is pursuing SaMD approval for depression severity assessment under Tokyo's AMDAP program.

PST generates revenue through VOISLOG cloud subscriptions (enterprise and SMB tiers), OEM/cloud licensing to platform partners (NTT Data BXO, Kort Valuta TwooCa, Wellville LIFE TALK ENGINE), WebAPI licensing, and future regulated SaMD sales via PST Medical. Go-to-market combines enterprise direct sales, channel partners (Hino Computer Systems for transportation), co-development partnerships with strategic players (Rohto Pharmaceutical, WISDOM, Sekisui Chemical, SOMPO), and government/municipal collaborations (Kanagawa Prefecture, Tokyo AMDAP). Customer segments span enterprise employers, transportation/logistics operators, nursing care facilities, SMBs (via government subsidy program), medical institutions, and local governments. The company received the EY Innovative Startup 2026 award and ASCO Breakthrough 2024 Abstract Award, among other recognitions.

PST firmographics

Firmographics
Name
PST
Legal name
PST株式会社
Website
https://medical-pst.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
1–10 employees
Short description
PST Inc. is a Yokohama-based biotechnology company that develops vocal biomarker technology analyzing voice source features to detect mental, neurological, cardiovascular, and cognitive health conditions, serving enterprise employers, transportation operators, medical institutions, and municipalities via its VOISLOG cloud platform and regulated SaMD programs.
Ownership category
akta.pro rank

PST industry classification

Industry
Product category
Voice-Based Health Diagnostics and Wellness Software
NAICS
Software Publishers (5132)
SIC
Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLACANAF
SaMD – Digital Biomarkers & Algorithmic Endpoints
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAD
Software as a Medical Device (SaMD) – Clinical Decision & Diagnostic Software
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAE
SaMD – Monitoring, Triage & Risk Stratification Software
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLALADAD
Chronic Condition Management & Remote Monitoring (e.g., diabetes, HTN)
Healthcare & Life Sciences/Telehealth Platforms/Employer-Sponsored Virtual Care Platforms

Keywords

  • Vocal biomarker technology
  • Voice-based health diagnostics
  • Cloud health monitoring platform
  • Medical software devices
  • Enterprise wellness analytics

Where PST is headquartered

Location

Headquarters

HQ city
Yokohama
HQ country
Japan
HQ region
Asia

Offices2 records

Markets served

PST business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D

Revenue model

  1. VOISLOG cloud platform subscription: VOISLOG is offered as a cloud-based SaaS platform with multiple apps (vAnalysis shared, vBG App) and management console (vManagement). Customers subscribe to access voice AI analysis and reporting. Revenue is primarily subscription-based with per-seat or organization-level pricing.
  2. IT導入支援事業者 subsidy (VOISLOG Standard Pack): VOISLOG標準パック[vAs+vM] is registered as an IT tool under the 中小企业デジタル化・AI導入支援事業費補助金, enabling SME customers to receive up to ¥1.5M in government subsidies toward subscription costs.
  3. OEM/cloud system licensing: PST provides cloud systems and WebAPI to OEM partners (enterprises, platforms) who embed voice biomarker technology into their own products and services. Partners integrate via API and pay licensing fees.
  4. Medical device software (SaMD) development and sales (PST Medical): PST Medical (subsidiary) is developing regulated medical device programs (Software as a Medical Device) for depression severity assessment and other clinical applications. Business model targets medical institutions and healthcare providers upon regulatory approval.
  5. Platform integration services (TwooCa, BXO): PST technology embedded in partner platforms (Kort Valuta TwooCa, NTT Data BXO) as licensed voice analysis engine, generating recurring licensing revenue from platform operators.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualVOISLOG標準パック [vAs+vM] — voice analysis app (vAnalysis shared) + management console (vManagement)

Go-to-market motion4 records

Distribution channels6 records

Marketing channels8 records

PST product offering

Product offering

Core offering

PST develops and sells a cloud-based vocal biomarker platform called VOISLOG that analyzes voice source features (not linguistic content) to detect mental, cognitive, cardiovascular, and physiological health conditions for enterprise wellness, transportation safety, elderly care, and clinical psychiatry applications. Through its subsidiary PST Medical, the company develops regulated Software as a Medical Device (SaMD) programs for depression severity assessment and cognitive screening, and operates the MIMOSYS legacy voice-based mental health monitoring system. Revenue is generated via SaaS subscriptions, OEM/API licensing, and government-subsidized SME deployments in Japan.

Product overview

PST Inc. operates as a vocal biomarker technology company offering two distinct product lines: (1) VOISLOG, a cloud-based healthcare voice analysis platform for corporate health management and wellness, and (2) disease-specific vocal biomarker technologies (VOISFIA) and medical device programs (SaMD) for the medical domain via its subsidiary PST Medical Inc. VOISLOG comprises multiple modules — voice analysis apps (vAnalysis individual and shared for shared devices), meeting-based analysis app (vBG App), administrative dashboards (vManagement), monthly Personal Report, and the vEQ emotional intelligence module — unified by the Mi-1 voice AI model. MIMOSYS is the legacy healthcare product. PST Medical focuses on clinical-grade depression severity assessment and cognitive screening as regulated medical devices. All technologies analyze raw voice source signals (not text) to detect involuntary physiological changes indicative of mental and physical health conditions.

Differentiator

Problem solved

Functional benefit

Brands

  • VOISLOG®: 日常会話などの音声を解析しストレス、睡眠、認知機能などの健康指標を推定するクラウドベースの音声解析プラットフォーム。スマートフォンアプリ(vAnalysis、vAnalysis shared)、リモート会議ツール(vBG App)、WebAPI管理システム(vManagement)を含む。
  • MIMOSYS®
  • VOISFIA®
  • PST Medical Inc. (PST MEDITCAL株式会社)
  • vEQ(Vocal Emotional Intelligence Quotient)

Products and services

  • VOISLOG Healthcare Platform Cloud-based voice analysis platform that visualizes mental and physical health conditions (stress, cognitive function, sleep, swallowing) from voice for corporate health management and wellness. Provides voice biomarker analysis via smartphone apps, remote meeting tools, WebAPI, and management dashboards for enterprise customers.
  • Depression Severity Assessment Tool (PST Medical SaMD) Medical device program under development by PST Medical Inc. for depression severity assessment using voice biomarkers. Estimates HAM-D scores with r=0.579 Pearson correlation and ROC-AUC 0.78-0.80 for HAM-D thresholds. Targeting SaMD approval for use by psychiatric hospitals and clinics.
  • Heart Failure Vocal Biomarker (VOISFIA) Disease-specific vocal biomarker for heart failure developed with Yokohama City University. Uses machine learning models with voice acoustic features to predict BNP levels (r=0.49) and NYHA class, achieving up to 80.4% accuracy in predicting cardiac test results for clinical use.
  • vAnalysis shared (Shared-Device Voice Analysis App) Voice analysis app optimized for shared device use in workplace settings (transportation, call centers, enterprises). Allows approximately 50 users per shared tablet/phone with guided reading or free speech measurement, auto-login, brief result display, and automatic logout for secure multi-user operation.
  • vBG App (Meeting Voice Analysis App) Desktop voice analysis app that runs in the background during remote or in-person meetings on Zoom, Microsoft Teams, Slack, Google Meet, LINE, and Webex. Automatically captures the registered user's voice only and analyzes stress and mental/physical condition changes without user intervention.
  • vManagement Personal Report Monthly structured personal health report feature within vManagement. Consolidates 1 month of voice analysis results, providing numerical/graphical trends plus natural language commentary authored with occupational health expert input, including self-care action recommendations.
  • vEQ (Vocal Emotional Intelligence Quotient Service) Voice-based Emotional Intelligence Quotient quantification service co-developed with WISDOM. Quantifies empathy from voice using the 'vEQ' empathy analysis algorithm (patent pending). Targets HR, talent development, and organizational EQ building for enterprise customers.
  • MIMOSYS (Mind Monitoring System) PST's foundational voice-based mental health assessment technology that visualizes mental states by analyzing voice changes including involuntary vocal cord tension. Exports Vitality, Mental Activity, and Mind Index scores. Available via SDK, WebAPI, and applications for healthcare and enterprise customers.
  • VOISLOG × TwooCa Ring Integration Integrated product combining VOISLOG voice biomarker analysis with the TwooCa Ring wearable device (Kort Valuta), merging voice analysis data with vital signs to generate composite health scores spanning physical, mental, and financial wellness for enterprise employees.
  • VOISLOG Standard Pack [vAs+vM] Standardized IT tool package combining vAnalysis shared (vAs) and vManagement (vM) cloud services for SMEs. Registered as an approved IT tool under Japan's SMB Digitalization/AI Adoption Subsidy program, enabling eligible businesses to receive up to 1.5 million yen in government subsidies.
  • Cognitive Impairment Screening Vocal Biomarker (VOISFIA) Disease-specific vocal biomarker for mild cognitive impairment (MCI) and dementia (Alzheimer's, DLB) developed with academic partners. Uses non-verbal acoustic features from simple speech tasks in machine learning models. Achieved mean AUC of 0.81 and 66.7% three-group correct classification (healthy/MCI/dementia) in validation.

Quantifiable outcome

  • Depression estimation: Pearson r=0.579; ROC-AUC 0.793 (HAM-D≥8), 0.780 (HAM-D≥14). Inter-visit monitoring: correlation 0.62, AUC=0.82, 77% accuracy, marginal R²=0.37 for symptom change prediction.
  • +4 more outcomes

Companies that use PST

Customer profile

Named customers6 records

Segments6 records

Ideal customer profiles5 records

PST technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

Integration10 records

AI capability7 records

Feature13 records

PST partnerships and signals

Strategic signal

Partnerships

18 partnerships are on record, tiered minor and core.

  • E-Gaia Progress (株式会社イーガイアプログレス)minorStrategic or Co-development Partner · 2 June 2026Joint development of municipality/community mental health and well-being support services. Combine PST's VOISLOG platform with E-Gaia Progress's auto-call and WELLXiL mental health services. Target: elderly monitoring, community care, ME-BYO improvement. Extension of existing enterprise mental health partnership.
  • WISDOM合同会社 (合同会社WISDOM)coreStrategic or Co-development Partner · 27 April 2026Joint development of vEQ (Vocal Emotional Intelligence Quotient) algorithm for quantifying empathy and EQ from voice. Patent filed jointly (特願2025-191230). WISDOM provides EQ training expertise; PST provides voice analysis technology. Target: enterprise EQ training (2026) and HR tech (2027+).
  • Hino Computer Systems (日野コンピューターシステム)coreChannel Partner/ Reseller/ Distributor · 27 April 2026Sales agent agreement for VOISLOG platform. Hino CS — IT provider within Hino Motor Group — distributes VOISLOG to transportation companies and other industries for driver condition monitoring at shift check-in and accident prevention.
  • Tokyo Marine DR (東京海上ディーアール)minorStrategic or Co-development Partner · 29 August 2025Collaboration on enterprise health management consulting. Combines Tokyo Marine DR's risk consulting expertise with PST's voice biomarker technology for corporate wellness programs targeting mental health, turnover reduction, and accident prevention in call centers and logistics.
  • Kanagawa Prefecture (神奈川県)coreStrategic or Co-development Partner · 30 May 2025Formal partnership agreement for voice-based ME-BYO indicator regional deployment. Upgrade of MIMOSYS to VOISLOG Mi-1. Collaboration on ME-BYO brand expansion, stress/cognitive/sleep/oral health service rollout, and community health improvement across Kanagawa Prefecture.
  • Rohto Pharmaceutical Co., Ltd. (ロート製薬)coreStrategic or Co-development Partner · 19 February 2025Strategic alliance to integrate vocal biomarker technology into Rohto's health and wellness ecosystem. Combined expertise aimed at developing products and services for mental health and preventive care, leveraging Rohto's pharmaceutical and consumer health platform.
  • Tokyo Metropolitan Government (AMDAP program)coreStrategic or Co-development Partner · 24 October 2024PST Medical selected for Tokyo's Advanced Medical Device Acceleration Project (AMDAP). Receives 3-year intensive support including dedicated catalyst (regulatory expert) mentoring, clinical/regulatory/IP/business guidance for developing depression severity SaMD.
  • Total Future Healthcare (トータルフューチャーヘルスケア)minorStrategic or Co-development Partner · 4 October 2024PST participates in Total Future Healthcare's cross-industry platform for early detection of falls and disease risk in living spaces. PST contributes voice biomarker data for health monitoring within the platform ecosystem.
  • Kort Valuta (株式会社Kort Valuta)coreTechnology or Integration · 26 July 2024Capital and business alliance. PST technology integrated into Kort Valuta's TwooCa digital employee badge (Visa payment + attendance + mental health check). Also Kort Valuta ring vital data + VOISLOG integration planned. FinTech × HealthTech partnership for 'money, body, mind' health.
  • Sekisui Chemical (積水化学工業)minorStrategic or Co-development Partner · 3 June 2024Joint development of cognitive function screening voice analysis algorithm. Clinical trial for cognitive function testing medical device initiated. Sekisui Chemical and PST co-developing the algorithm for commercialization.
  • UIX Corporation (UIX株式会社)minorStrategic or Co-development Partner · 1 July 2023Joint venture (PST + FlexibleCreation) operating 'Sofuto Visiting Nursing Station' in Yokohama Isogo-ku. Next-generation visiting nursing service combining PST voice analysis, AI/IT technology, and cloud PBX with electric kickboard mobility.
  • NTT Data Japan (株式会社NTTデータ)coreTechnology or Integration · 30 March 2023MIMOSYS voice biomarker technology OEM-integrated into NTT Data's BXO Hybrid Workspace for Employee Experience (BXO Well-being module). Enables NTT Data to offer voice-based mental health monitoring to enterprise clients in hybrid work environments.
  • JST COI-NEXT Metaverse Platform (JST共創の場形成支援プログラム)minorStrategic or Co-development Partner · 25 October 2022PST participates in Yokohama City University-led 'Meta Care City' project (JST COI-NEXT 共創分野本格型). Contributes voice pathophysiology analysis as health quantification tool in virtual care environments targeting youth psychological resilience.
  • SOMPO Holdings / SOMPO Care (積水化学工業+SOMPOケア)minorStrategic or Co-development Partner · 9 February 2022Joint R&D on swallowing function evaluation technology using voice analysis via smartphone/tablet. Aimed at visualizing aspiration risk in elderly populations. Planned 2022 commercialization.
  • Kyoto University Hospital / Kyoto University Graduate School of Medicine (京都大学医学部附属病院・京都大学大学院医学研究科)coreStrategic or Co-development Partner · 8 October 2021Joint research on voice-based QOL management for gynecological cancer patients and depression assessment. Multiple papers published, ASCO Breakthrough Abstract Award received. Co-development of depression severity estimation model with 2026 clinical results published.
  • Yokohama City University / Yokohama City University Medical Center (横浜市立大学・附属総合医療センター)coreStrategic or Co-development PartnerLong-standing joint research on heart failure vocal biomarkers with Dr. Kozo Okada. Multiple publications including AHA Scientific Session, Japan Circulation Society, and Circulation Reports. Also collaborated on congenital heart disease seminar (2024).
  • Welby (不是我认识的合作伙伴 - listed in joint users)minorOthersListed in PST privacy policy joint user list.
  • Kanagawa University of Human Services (神奈川県立保健福祉大学)minorStrategic or Co-development PartnerJoint research with Prof. Shinichi Tokuno on COVID-19 severity discrimination from voice, published 2023 in Int J Env Res Public Health.

Scale indicators7 records

Recent moves7 records

Expansion highlights7 records

PST competitors and assessment

Company assessment

Direct peers

  • Kintsugi: US-based voice biomarker startup quantifying depression/anxiety from short voice samples for payers and digital health platforms. Closely parallels PST's depression model, enterprise wellness integration and SDK/API distribution.
  • Winterlight Labs: Canada-based voice biomarker company focused on cognitive and CNS endpoints for clinical trials (Alzheimer's, MCI, schizophrenia). Comparable to PST's cognitive impairment/dementia vocal biomarker module and clinical-research focus.
  • Ellipsis Health: US-based vocal biomarker startup that analyzes voice to detect depression and anxiety symptoms for health systems and payers. Closely mirrors PST's depression/severe-mental-health scoring use case and clinical validation strategy.
  • CureApp: Japanese digital therapeutics (DTx/SaMD) company with PMDA-approved nicotine-dependence and hypertension apps. Highly comparable to PST Medical on Japanese SaMD regulatory pathway, reimbursement and clinical-deployer GTM.
  • Sonde Health: US-based vocal biomarker company offering voice-based mental and physical health monitoring (depression, stress, cognitive decline, respiratory conditions). Directly comparable to PST on technology approach, biomarker focus areas and SaaS/API delivery model.

Broad incumbents

  • Omada Health: US-based broader digital health platform offering chronic condition prevention and management (diabetes, hypertension, mental health) to employers and payers. Comparable in B2B2C employer-wellness GTM and condition-specific digital interventions, though vaster scale and broader scope.

Regional players

  • MICIN: Japanese digital health company offering online medical consultations, remote patient monitoring and AI-assisted triage to hospitals, pharmacies and insurers. Comparable regional peer serving overlapping Japanese enterprise/healthcare buyers with adjacent digital health services.

Emerging players

  • Canary Speech: US-based vocal biomarker startup applying voice analysis to early detection of cognitive decline, mental health and neurodegenerative conditions. Overlaps with PST on vocal biomarker R&D focus, though still pre-commercial compared to PST's Japanese deployments.
  • Beyond Verbal: Israel-based voice analysis company that decodes health and emotional biomarkers from vocal acoustics. Earlier-stage peer in the same vocal biomarker category as PST, with overlapping emotion/mood-disorder detection product thinking.

Others

  • Modulate (Modulate AI): US-based voice analytics company that detects emotion, toxicity and engagement from speech on platforms like Discord and games. Adjacent rather than directly competitive, but comparable as a voice-as-signal AI infrastructure provider powering third-party platforms.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

PST social profiles

Digital presence

PST compliance and trust

Trust signal

Compliance2 records

PST financial estimates

Financial estimate

Revenue estimate

Valuation estimate

PST leadership team

Management profile

Number of profiles

Profiles2 records

PST subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

PST funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

PST M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PST

What does PST do?

PST develops and sells a cloud-based vocal biomarker platform called VOISLOG that analyzes voice source features (not linguistic content) to detect mental, cognitive, cardiovascular, and physiological health conditions for enterprise wellness, transportation safety, elderly care, and clinical psychiatry applications. Through its subsidiary PST Medical, the company develops regulated Software as a Medical Device (SaMD) programs for depression severity assessment and cognitive screening, and operates the MIMOSYS legacy voice-based mental health monitoring system. Revenue is generated via SaaS subscriptions, OEM/API licensing, and government-subsidized SME deployments in Japan.

Is PST a public or private company?

PST is a private company. It is classified as venture growth investor backed and is currently operating.

When was PST founded?

PST was founded in 2012. It employs 1 to 10 people.

Where is PST based?

PST is headquartered in Yokohama, Japan, in the Asia region.

How does PST make money?

Five revenue lines are on record. VOISLOG cloud platform subscription is the primary driver. The others are IT導入支援事業者 subsidy (VOISLOG Standard Pack), OEM/cloud system licensing, medical device software (SaMD) development and sales (PST Medical) and platform integration services (TwooCa, BXO).

Who are PST's main competitors?

Direct peers on record are Kintsugi, Winterlight Labs, Ellipsis Health, CureApp and Sonde Health. Omada Health is listed as a broad incumbent. MICIN is listed as a regional player. Emerging players are Canary Speech and Beyond Verbal. Modulate (Modulate AI) is listed as an others.

Does PST have an API?

Yes. PST provides a WebAPI that customers can use online to implement various vocal biomarker technologies in their own applications. By posting acquired voice data to the WebAPI, customers can retrieve vocal biomarker data. Customers are responsible for implementing functions for voice data acquisition and building their own database for storing the retrieved vocal biomarker data. The WebAPI is offered as part of the VOISLOG platform's technology offerings for healthcare. The company also offers an SDK (Software Development Kit) as part of its historical MIMOSYS product line.

What industry is PST in?

PST's product category is Voice-Based Health Diagnostics and Wellness Software. Its primary akta.pro industry code is HLACANAF, SaMD – Digital Biomarkers & Algorithmic Endpoints, with a secondary code of HLACANAD, Software as a Medical Device (SaMD) – Clinical Decision & Diagnostic Software. Its NAICS code is 5132 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingLeifras signs business agreement with PST to deploy VOISLOG voice analysis platformLeifras signed a business agreement with PST to deploy PST's VOISLOG voice-analysis platform across its sports instruction network. The initial rollout targets employees and instructors, with expansion planned for about 70,688 members across over 4,500 sports schools in Japan. The deal also makes Leifras a VOISLOG distributor for sales and referrals.PrtimesVisualizing emotional intelligence (EQ) from 'voice'! The birth of the 'Voice EQ Empathy Technology Service (patent pending)' that connects to human resource development in the AI era.PST Corporation and WISDOM LLC jointly developed vEQ, a technology that objectively visualizes emotional intelligence from human voices. The technology, with a patent application pending, aims to connect to human resource development in the AI era.PR NewswireПрефектура Канагава проводит «ME-BYO Summit Kanagawa» для создания «стареющего общества с улыбкой до 100 лет» путём визуализации «ME-BYO» - предсимптоматического состояния постоянного перехода между зKanagawa Prefecture in Japan held the ME-BYO Summit Kanagawa in October 2017, featuring the ME-BYO Japan 2017 technology exhibition at Pacifico Yokohama, to promote the concept of ME-BYO — a pre-symptomatic transitional state between health and illness — as part of its goal to create an aging society where people remain healthy and active up to 100 years. The three-day exhibition attracted over 15,000 visitors and showcased certified ME-BYO BRAND health monitoring technologies including MIMOSYS by PST Inc., fatigue assessment systems by Fatigue Science Laboratory Inc., HAL robot suits by CYBERDYNE Inc., and IoT Smart Home by NTT Docomo. The summit also included conferences with WHO experts to develop standardized ME-BYO indices for predicting metabolic health risks in partnership with the Center for Innovation at the University of Tokyo.